drugset
drugset / Trial / NCT02533934

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

NCT02533934 ↗

Phase 4 Completed 68 enrolled University of California, San Francisco Columbia University · collabGeorgetown University · collabIcahn School of Medicine at Mount Sinai · collabJohns Hopkins University · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collabNational Institutes of Health Clinical Center (CC) · collabUniversity of Maryland, College Park · collabUniversity of Pennsylvania · collab
NaSingle-groupOpen-labelTreatment

Summary

Retrospective/Prospective, open-label study using sofosbuvir based DAA therapy to treat HIV/HCV coinfected pre or post liver transplant participants

Timeline

Start
2016-08
Primary completion
2019-12-31
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Sofosbuvir Small molecule — —

Indications

HIV infectious disease cirrhosis of liver hepatitis C virus infection